menu
    • menu

    Company profile for UCB Pharma S.A

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    A global biopharma focused on severe diseases with operations in approximately 40 countries and global revenue of € 3.3 billion in 2014. We combine biology and chemistry to make major breakthroughs. By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules ...
    A global biopharma focused on severe diseases with operations in approximately 40 countries and global revenue of € 3.3 billion in 2014. We combine biology and chemistry to make major breakthroughs. By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs. We partner with the leaders in the pharmaceutical industry. The complexities of severe diseases are beyond the expertise and resources of a single organisation.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    UCB Pharma S.ABelgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Allée de la Recherche, 60 1070 Brussels
    Telephone
    Telephone
    +32 2 559 99 99
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ucb.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Results for UCB's Fintepla pave way for 3rd epileptic indication
    Results for UCB's Fintepla pave way for 3rd epileptic indication

    08 Dec 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/fast-rising-ucb-set-file-approval-fintepla-3rd-epileptic-disorder

    FIERCE PHARMA
    08 Dec 2025
    Share Share
    FDA Approves Kygevvi for TK2D in Adults & Children
    FDA Approves Kygevvi for TK2D in Adults & Children

    07 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/us-fda-approves-kygevvi-doxecitine-and-doxribtimine-the-first-and-only-treatment-for-adults-and-children-living-with-thymidine-kinase-2-deficiency-tk2d-302603083.html

    PR NEWSWIRE
    07 Nov 2025
    Share Share
    UCB’s Kygevvi Receives Approval in US
    UCB’s Kygevvi Receives Approval in US

    03 Nov 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219792

    FDA
    03 Nov 2025
    Share Share
    Bimzelx Data Show 3-Year Pain And Tunnel Resolution Gains in HS
    Bimzelx Data Show 3-Year Pain And Tunnel Resolution Gains in HS

    31 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bimzelx-bimekizumab-bkzx-data-in-hidradenitis-suppurativa-showed-improvements-in-pain-and-resolution-of-draining-tunnels-sustained-to-three-years-302601303.html

    PR NEWSWIRE
    31 Oct 2025
    Share Share
    UCB Initiates 2026 Myasthenia Gravis Scholarship Applications
    UCB Initiates 2026 Myasthenia Gravis Scholarship Applications

    29 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ucb-opens-applications-for-2026-ucb-myasthenia-gravis-scholarship-302598564.html

    PR NEWSWIRE
    29 Oct 2025
    Share Share
    Ucb to Present New gMG Data for Rystiggo and Zilbrysq
    Ucb to Present New gMG Data for Rystiggo and Zilbrysq

    29 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ucb-to-unveil-new-data-for-rystiggo-rozanolixizumab-noli-and-zilbrysqzilucoplan-for-gmg-at-the-2025-aanem-annual-meeting-and-mgfa-scientific-session-302595949.html

    PR NEWSWIRE
    29 Oct 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

    Details:

    Rozanolixizumab is a antibody candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Myasthenia Gravis.


    Lead Product(s): Rozanolixizumab,Inapplicable

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 24, 2025

    blank

    01

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Rozanolixizumab,Inapplicable

    Therapeutic Area : Immunology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With...

    Details : Rozanolixizumab is a antibody candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Myasthenia Gravis.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    November 24, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants

    Details:

    UCB0022 (glovadalen) is a small molecule which is currently being evaluated in Phase I clinical studies for the treatment of Anemia, Sickle Cell.


    Lead Product(s): Glovadalen,Inapplicable

    Therapeutic Area: Genetic Disease Brand Name: UCB0022

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 24, 2025

    blank

    02

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Glovadalen,Inapplicable

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants

    Details : UCB0022 (glovadalen) is a small molecule which is currently being evaluated in Phase I clinical studies for the treatment of Anemia, Sickle Cell.

    Product Name : UCB0022

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    October 24, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bimekizumab Efficacy and Safety in Palmoplantar Pustulosis

    Details:

    Bimekizumab is a antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Psoriasis.


    Lead Product(s): Bimekizumab,Inapplicable

    Therapeutic Area: Dermatology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 21, 2025

    blank

    03

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bimekizumab,Inapplicable

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Bimekizumab Efficacy and Safety in Palmoplantar Pustulosis

    Details : Bimekizumab is a antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Psoriasis.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    October 21, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zilucoplan for Severe gMG Exacerbations

    Details:

    Zilucoplan is a Protein drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Myasthenia Gravis.


    Lead Product(s): Zilucoplan Sodium,Inapplicable

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Protein

    Sponsor: Miriam Freimer

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 14, 2025

    blank

    04

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Zilucoplan Sodium,Inapplicable

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Miriam Freimer

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Zilucoplan for Severe gMG Exacerbations

    Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Myasthenia Gravis.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    October 14, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Tanner Pharma, UCB Pharma Partner for Epilepsy Program in Southeast Asia

    Details:

    The partnership aims to advance the clinical development of an undisclosed controlled substance in an undisclosed target.


    Lead Product(s): Undisclosed,Inapplicable

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Controlled Substance

    Sponsor: Tanner Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership October 01, 2025

    blank

    05

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed,Inapplicable

    Therapeutic Area : Neurology

    Highest Development Status : Undisclosed

    Partner/Sponsor/Collaborator : Tanner Pharma

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Tanner Pharma, UCB Pharma Partner for Epilepsy Program in Southeast Asia

    Details : The partnership aims to advance the clinical development of an undisclosed controlled substance in an undisclosed target.

    Product Name : Undisclosed

    Product Type : Controlled Substance

    Upfront Cash : Undisclosed

    October 01, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Onset of Action of Staccato Alprazolam Vs. Midazolam/Diazepam

    Details:

    Midazolam is a Controlled Substance drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.


    Lead Product(s): Midazolam,Alprazolam,Diazepam

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Controlled Substance

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 13, 2025

    blank

    06

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Midazolam,Alprazolam,Diazepam

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Onset of Action of Staccato Alprazolam Vs. Midazolam/Diazepam

    Details : Midazolam is a Controlled Substance drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

    Product Name : Undisclosed

    Product Type : Controlled Substance

    Upfront Cash : Inapplicable

    June 13, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

    Details:

    Glovadalen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


    Lead Product(s): Glovadalen,Inapplicable

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 14, 2025

    blank

    07

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Glovadalen,Inapplicable

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasia...

    Details : Glovadalen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    May 14, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

    Details:

    Zilucoplan is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


    Lead Product(s): Zilucoplan Sodium,Inapplicable

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Protein

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 08, 2025

    blank

    08

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Zilucoplan Sodium,Inapplicable

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

    Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    May 08, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

    Details:

    Bimekizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hidradenitis Suppurativa.


    Lead Product(s): Bimekizumab,Inapplicable

    Therapeutic Area: Dermatology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 10, 2025

    blank

    09

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bimekizumab,Inapplicable

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With ...

    Details : Bimekizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hidradenitis Suppurativa.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    April 10, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

    Details:

    Bimekizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psoriasis.


    Lead Product(s): Bimekizumab,Inapplicable

    Therapeutic Area: Dermatology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 21, 2025

    blank

    10

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed

    UCB Pharma S.A

    Belgium
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bimekizumab,Inapplicable

    Therapeutic Area : Dermatology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Tr...

    Details : Bimekizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psoriasis.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    March 21, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact UCB, Inc and get a quotation

    UCB, Inc is a supplier offers 16 products (APIs, Excipients or Intermediates).

    Find a price of Cetirizine Dihydrochloride bulk with DMF offered by UCB, Inc

    Find a price of Buclizine Hydrochloride bulk offered by UCB, Inc

    Find a price of Calcitonin bulk offered by UCB, Inc

    Find a price of Carbetapentane bulk offered by UCB, Inc

    Find a price of Hydroxyzine Hydrochloride bulk offered by UCB, Inc

    Find a price of Hydroxyzine Pamoate bulk offered by UCB, Inc

    Find a price of Meclizine Hydrochloride bulk offered by UCB, Inc

    Find a price of Mesna bulk offered by UCB, Inc

    Find a price of Methylphenidate Hydrochloride bulk offered by UCB, Inc

    Find a price of Pentoxiverine citrate bulk offered by UCB, Inc

    Find a price of Piracetam bulk offered by UCB, Inc

    Find a price of FACILITIES AND GENERAL OPERATING PROCEDURES bulk offered by UCB, Inc

    Find a price of FACILITIES, PERSONNEL AND GENERAL OPERATING PROCEDURES bulk offered by UCB, Inc

    Find a price of Brivaracetam bulk offered by UCB, Inc

    Find a price of Lacosamide bulk offered by UCB, Inc

    Find a price of Levetiracetam bulk offered by UCB, Inc

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search